Differentiation syndrome with lower?intensity treatments for acute myeloid leukemia

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is well-known treatment-related complication promyelocytic (APL), efforts are still ongoing to standardize diagnostic parameters AML. Though the rates incidence vary, many signs symptoms common between APL So, can lead fatal complications AML, but prompt management usually effective rarely necessitates interruption or discontinuation AML therapy.